Action RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Reviva Pharmaceuticals Holdings, Inc.

Actions

RVPH

US76152G1004

Marché Fermé - Nasdaq
Autres places de cotation
 19:00:00 03/07/2024 		Varia. 5j. Varia. 1 janv.
1,07 USD -0,93% Graphique intraday de Reviva Pharmaceuticals Holdings, Inc. -14,40% -79,22%
11/06 REVIVA PHARMACEUTICALS HOLDINGS, INC. : HC Wainwright à l'achat ZM
28/05 Riviva Pharmaceuticals fixe le prix d'une offre d'actions et de bons de souscription de 3 millions de dollars ; les actions chutent MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
Reviva to Participate in the BIO International Convention
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RVPH
  4. Actualités Reviva Pharmaceuticals Holdings, Inc.
  5. Autres langues